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changes in response to coronary ESC perfusion, including declines in CF, HR, LVP, +dp/
dtmax, and –dp/dtmax, with increased ESC perfusion rates. However, the magnitude of
these parameters differed between the two mouse strains. At less than 106 cells/ml/min,
the percent decline of these parameters in wild type hearts appeared significantly greater
(p<0.05) than those of apoE-/-: CF 15.2% in wild type vs. 10% in apoE-/-, HR 19% vs.
7%, LVP 9% vs. 6%, +dp/dtmax 11% vs. 8%, and –dp/dtmax 24% vs. 11%. Increasing
the perfusion rates up to 5x106 cells/ml/min led to further deterioration of the heart func-
tions but the apoE-/- hearts remained lower levels of the parameter declines. Histopatho-
logical analysis showed the presence of numerous ESC in microcirculation as well as in
the extravascular tissue.
Conclusions: Perfusion with ESC through coronary arteries causes concentration-
dependent changes in heart function. Compared to wild type controls, the hearts of
apoE-/- mice which underwent atherosclerosis-related chronic ischemia appeared to be
better tolerant to high ESC perfusion.
1011-109 The Mitochondrial Metabolic Phenotype and Mouse 
Strain Influence Isoproterenol-Induced Cardiac 
Hypertrophy
Michael Faulx, Michael S. Zawaneh, Margaret P. Chandler, William C. Stanley, Brian D. 
Hoit, Case Western Reserve University, Cleveland, OH, University Hospitals of 
Cleveland, Cleveland, OH
Introduction We previously described a novel model of isoproterenol (ISO)-induced
hypertrophy in which A/J mice exhibit greater cardiac hypertrophy than B6 mice. The
objective of this study was to determine the relation between this variable hypertrophic
response and the mitochondrial metabolic phenotype.
Methods 39 male mice (19 A/J, 20 B6) received randomly either ISO (100 mg/kg, sc) or
vehicle daily for five days. Hearts were assayed for the genomically-expressed mitochon-
drial enzymes pyruvate dehydrogenase (PDH), medium chain acyl-CoA dehydrogenase
(MCAD), carnitine palmitoyl transferase I (CPT-I) and citrate synthase activities. Nine
consomic B6.AM mice (B6 containing mitochondrial DNA from A/J) were also studied.
Results ISO-treated A/J mice displayed a greater increase in gravimetric heart/body
weight (vs. vehicle) than ISO-treated B6 (24% vs. 3%, respectively, p<0.001). Enzyme
activities were greater in vehicle-treated B6 than A/J mice (Table). ISO administration
reduced active PDH activity (PDHa) in B6 mice by 47% (p<0.001), with no significant
change in A/J. The hypertrophic response and basal and stimulated enzyme activites
were similar in B6.AM and B6 mice.
Conclusions 1) Compared to A/J, B6 mice demonstrate less ISO-induced cardiac hyper-
trophy, but greater activity of fatty acid and carbohydrate oxidative enzymes. 2) ISO-
induced hypertrophy reduces myocardial PDH in a strain-dependent manner. 3) These
mitochondrial enzyme activities are not influenced by mitochondrial DNA.
1011-110 The HNO/Nitric Oxide Donor Angeli’s Salt Enhances 
Myocyte Contractility in a PKA-Dependent Manner
Carlo G. Tocchetti, Tatsuo Katori, Manuela Zaccolo, Daniele Mancardi, Diego F. Belardi, 
Katrina M. Miranda, David A. Wink, David A. Kass, Nazareno Paolocci, Johns Hopkins 
University, Baltimore, MD, NIH, Bethesda, MD
Background: Nitroxyl anion (HNO/NO-) donors exert similar positive inotropic/lusitropic
effects in normal and failing hearts in vivo that are not reproduced by NO/nitrate donors.
These effects are partly linked to calcitonin gene-related peptide (CGRP) release. We
hypothesize that the HNO/NO- donor Angeli’s Salt (AS) has a direct positive inotropic
effect on myocyte contractility.
Methods: Cardiac myocytes were isolated from wild type 1-4 month old mice, sus-
pended in Tyrode’s solution (1.8 mM calcium) and field stimulated at 0.5 Hz at 23°C. Sar-
comere shortening (SS) was assessed by real-time image analysis, and Ca2+ transients
from Indo-1 fluorescence. Data are presented at steady-state (10 minutes AS infusion).
Results: AS induced a dose-dependent inotropic response (SS: +17±3% at 0.1 mM,
n=5; +28±7% at 0.25 mM, n=9; +89±12% at 0.5 mM, n=8; +135±21% at 1 mM, n=11; all
p<0.01 versus baseline). Peak Ca2+ transients increased +18±7% at 0.25 mM (p=0.05,
n=5). To test a role of Protein Kinase A (PKA) stimulation by AS, experiments were
repeated in the presence of the PKA-inhibitor H89 (5 µM). AS-induced inotropy was fully
reversed by H89 (-100±33%) at 0.5 mM AS, and partially blunted (-74±42%) at 1 mM
(both n=4). In striking contrast, 10 min infusion of the NO-donor DEA/NO at 0.05 and
0.125 mM (equivalent to 0.1 and 0.25 mM AS) reduced SS -63±6% (p<0.001 vs AS 0.1
mM, n=5) and -21±11% (p=0.002 vs AS 0.25 mM, n=8), respectively, without altering
Ca2+ transients. Higher DEA/NO doses did not depress contractility, but yielded insignifi-
cant changes that remained well below the positive effects of AS (e.g. 33±16% at DEA/
NO 0.5 mM, <20% of the AS 1 mM response, p=0.001, n=16).
Conclusion: The HNO/NO- donor AS directly enhances myocyte contractility in a dose-
dependent manner that differs markedly from NO-donors. AS inotropy is coupled to an
increase in Ca2+ transients and blunted by PKA inhibition, supporting involvement of
cAMP/PKA dependent signaling.
1011-111 Homocysteine Promotes Ventricular Remodeling by 
Induction of Apoptosis of Rabbit Cardiomyocytes and 
Priming the Mast Cells to Induce Interleukin-6, With 
Significant Inhibition by Troglitazone
Bahaeddin A. Shabaneh, Wassim Mouannes, Steven Lee, Matthew Fitzgerald, Kenton 
Hall, Steve Armstrong, Guha Krishnaswamy, East Tennessee State University, Johnson 
City, TN
Background:
Homocysteine (HCy) has been linked to the pathophysiology of atherosclerosis, on the
other hand, it has been linked to ventricular remodeling and heart failure through pro-
inflammatory causes. This may occur due to direct effects on the cardiomyocytes or indi-
rectly by involving other cells like macrophages, fibroblasts and mast cells.
Methods:
After isolating rabbit cardiomyocytes ( CMs ) using the standard perfusion method, we
have given d,l HCy ( 1x 10-4 M ) to the cells and at three hours we quantitated the apop-
totic cells using Flow Cytometry. We used Annexin V ( FITC ) - Propidium Iodide method
for apoptosis detection. Apoptotic cells manifest as Annexin V - FITC positive and Propid-
ium Iodide negative, while necrotic cells manifest as Annexin V - FITC positive and PI
positive. We have also given d,l HCy to Human Leukemic Mast Cells (HMC-1) with 1 ng/
mL of Interleukin 1 beta ( IL1b ) in a dose dependent manner ( 10, 50 , 100 x 10-6 M). We
added the Peroxisome Proliferator Activated Receptors (PPAR) gamma agonist ( Troglita-
zone ) to the cells as well ( 10 x10-6 M ). We used ELISA technique to quantitate the
amount of Interleukin 6 ( IL 6 ) in the supernatants after 24 hours of incubation.
Results:
We found that d,l HCy induces apoptosis of CMs in the HCy group ( 3.0% versus 1.0 %
control , p = 0.02 ) . On the other hand, we noticed a dose dependent increase in IL 6
concentration in response to stimulation of HMC1 cell line with a small fixed dose of IL1b
and increasing doses of d,l Hcy ( 35 pg/mL versus 75 pg/mL , for IL1b alone versus IL1b
+ HCY 100x10-6 , p= 0.004). Surprisingly, adding Troglitazone to the HCy - IL1b - HMC-1
solution blunted the stimulatory response ( 35 pg/mL versus 15 pg/mL, p =0.045 ). Low
concentration Troglitazone in a separate study did not kill HMC-1 cell line per flow cytom-
etry and viability methods.
Conclusions:
HCy induces apoptosis of rabbit cardiomyocytes, and to our knowledge this is the first
experiment that documents this finding . Moreover, HCy primes the mast cells to the
effects of IL1b to produce IL6, this was blunted by PPAR inhibition. Apoptosis and IL6 are
involved in ventricular remodeling and heart failure. Further testing is warranted to study
the various effects of HCy on cardiomyocytes.
1011-112 Use of Abciximab Prior to Primary Angioplasty in ST-
Segment Elevation Myocardial Infarction Results in 
Early Recanalization of the Infarct-Related Artery: 
Results of the Multicenter Randomized ReoPro-
BRIDGING Study
Mariann Gyongyosi, Hans Domanovits, Birgit Heinisch, Wolfgang Benzer, Morritz Haugk, 
Kurt Huber, The ReoPro-BRIDGING Study Group, University of Vienna, Vienna, Austria
Background. The ReoPro-BRIDGING Austrian multicenter randomized study investi-
gated the effect of Abciximab (ReoPro) on infarct-related artery (IRA) patency and early
reperfusion prior to primary coronary intervention (pPCI).
Methods. Thirty-eight patients with ST-segment elevation AMI were treated with ReoPro
0.25 mg/kg bolus followed by 10 ug/min infusion and randomized either to start ReoPro
during the organization time (66±33 min) for pPCI (Group 1, n=18) or immediately after
pPCI (Group 2, n=20). Serial measurements of creatine kinase (CK), CKMB, myoglobin,
and 12-lead ECG were performed at baseline as well as 2, 4, 6, 8, 10, 12, 24 and 48 h
thereafter.
Results. A trend to a more rapid and higher release of cardiac enzymes was observed in
patients of Group 1: rate of rise of CK 164±203 vs 127±170 U/l/min; CKmax: 922±954 vs
776±644 U/L, CKMBmax: 120±72 vs 105±85 U/l and myoglobin max. 1399±1092 vs
909±943 ng/ml (Fig.1). ST-segment resolution >50% occurred in 12 patients (67%) in
Group 1 and 6 patients (30%) in Group 2 (p=0.024) before pPCI. TIMI flow 0 was
observed in 6 (33%) vs 11 patients (55%) of Group 1 vs 2 (p=0.3). Corrected TIMI frame
count was significantly lower (57±33 vs 76±22 frames, p=0.034) and angiographic mini-
mal lumen diameter was larger (0.70±0.76 vs 0.29±0.39 mm, p=0.020) in patients of
Group 1.
Conclusions. Use of ReoPro in the organization phase for pPCI results in early and bet-
ter recanalization of the infarct-related artery prior to pPCI with a consecutive rapid
release of cardiac enzymes.
Data are mean ± SEM. * p<0.01 B6 vs. A/J by ANOVA. † p<0.001 ISO vs. 
vehicle by t-test.
A/J vehicle B6 vehicle A/J ISO B6 ISO
Citrate synthase (µmol/min/gww) 59 ±  4 171 ±  5 * 56 ±  3 163 ±  6
MCAD (µmol/min/gww) 10.4 ±  1.1 11.7 ±  0.9 * 8.9 ±  0.9 13.2 ±  0.9
CPT-1 (µmol/min/gww) 1.7 ±  0.1 2.4 ±  0.2 * 1.5 ±  0.1 2.4 ±  0.2
PDH active (U/gww) 2.2 ±  0.4 4.8 ±  0.5 * 1.9 ±  0.3 2.5 ±  0.3 †
